5.05

2.23% 0.11

Pre-market: 5.12 0.07 +1.39%

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $5.05, with a volume of 2.23M. It is up +2.23% in the last 24 hours and up +7.22% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Previous Close:

$4.94

Open:

24h Volume:

2.23M

Relative Volume:

0.74

Market Cap:

$808.81M

Revenue:

$181.41M

Net Income/Loss:

$-59.56M

P/E Ratio:

-12.02

EPS:

-0.42

Net Cash Flow:

$-38.83M

1W Performance:

+4.55%

1M Performance:

+7.22%

6M Performance:

+49.41%

1Y Performance:

+123.95%

1-Day Range:

$4.87

$5.105

1-Week Range:

$4.71

$5.105

52-Week Range:

$2.03

$6.07

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1166)

Industry

Biotechnology (665)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

394

Twitter

@XerisPharma

Next Earnings Date

2024-12-08

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	5.05	773.55M	181.41M	-59.56M	-38.83M	-0.42
ONC Beone Medicines Ltd Adr	245.93	25.76B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.43	114.53B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.415	40.54M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	84.10	6.44B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.81	65.13B	14.09B	4.50B	2.96B	39.28

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

03:30 AM

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Holdings Lessened by Ameriprise Financial Inc. - Defense World

03:30 AM

Jun 02, 2025

XERS: Key Highlights from Analyst and Investor Day | XERS Stock News - GuruFocus

Jun 02, 2025

ProShare Advisors LLC Cuts Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Jun 02, 2025

Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $273,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Jun 01, 2025

May 31, 2025

Bank of America Corp DE Sells 17,544 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

May 31, 2025

May 30, 2025

Deutsche Bank AG Grows Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

May 30, 2025

May 28, 2025

Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

May 28, 2025

May 27, 2025

BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

May 27, 2025

May 25, 2025

Xeris Biopharma (NASDAQ:XERS) Cut to “Hold” at Wall Street Zen - Defense World

May 25, 2025

May 23, 2025

Northern Trust Corp Purchases 38,155 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

May 23, 2025

May 22, 2025